HANS MOEBIUS - 18 Jan 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Chief Medical Officer
Signature: /s/ Glenna Mileson, Attorney-in-fact for Hans Moebius
Issuer symbol: ATHA
Transactions as of: 18 Jan 2022
Net transactions value: +$10,371
Form type: 4
Filing time: 20 Jan 2022, 16:25:42 UTC
Previous filing: 21 Jul 2021
Next filing: 24 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$10,371	+829	+2.7%	$12.51	31,256	18 Nov 2021	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Award	$0	+180,000		$0.000000	180,000	18 Jan 2022	Common Stock	180,000	$10.64	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).
F2	The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.
F4	One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.